Denali, ALS

Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a six-month study.
Denali Therapeutics Says ALS Trial Didn't Meet Endpoints
Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.
Denali Therapeutics’ Phase II/III trial of ALS therapy fails to meet primary endpoint
The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
Denali Therapeutics' ALS drug fails in mid-to-late stage trial
Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
Denali Therapeutics announces HEALEY ALS trial regimen misses endpoints
Denali Therapeutics (DNLI) announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B
ALS drugs from Denali, Calico come up short, marking more failures for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.
BioSpace3h
Denali Suffers Another ALS Fail With Phase II/III Flop
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More
Nvidia stock rises after the artificial-intelligence chip maker unveils its next generation gaming graphic cards, while ...
clinicaltrialsarena51m
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial
Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.
Geologists Solve a 620-Mile Mystery: The Forgotten History of the Denali Faults
New research on the Denali Fault reveals three geologic sites were once united in a suture zone, marking the integration of ...
Denali Water Solutions says stink in River Valley caused no ‘physical harm’
Fort Smith area plaintiffs have not shown they suffered physical harm from an intermittent but widespread offensive smell in ...
Science Daily10d
Denali Fault tore apart ancient joining of two landmasses
New research shows that three sites spread along an approximately 620-mile portion of today's Denali Fault were once a smaller united geologic feature indicative of the final joining of two land ...
Fairbanks Daily News-Miner2d
Denali Bancorporation increases dividend to $0.85 per share
Denali Bancorporation, Inc., the parent company of Denali State Bank, announced a $0.05 increase in its quarterly cash ...
On screen: Wampanoag character makes first appearance on PBS' national 'Molly of Denali'
Mashpee Wampanoag educator Kitty Hendricks-Miller (Nanaweetah), consults on PBS 'Molly of Denali' as Cape-based tribe debuts ...
Hosted on MSN3d
William Blair Initiates Coverage of Denali Therapeutics (DNLI) with Outperform Recommendation
Fintel reports that on January 3, 2025, William Blair initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a ...